Sign in

You're signed outSign in or to get full access.

Greg Fraser

Research Analyst at TD Cowen

Greg Fraser's questions to Moderna (MRNA) leadership

Question · Q4 2025

Greg Fraser asked for an explanation of the higher-than-expected cash balance at year-end and details on additional levers to lower cash costs moving forward.

Answer

Jamey Mock, CFO, explained that the higher year-end cash balance was due to beating original cash cost guidance by $1.2 billion, a $600 million initial draw from the credit facility, $100 million less in capital expenditures, and strong working capital performance (receivables at $180 million, inventory flat at $270 million, payables at $300 million, net working capital of $150 million).

Ask follow-up questions

Fintool

Fintool can predict Moderna logo MRNA's earnings beat/miss a week before the call

Question · Q4 2025

Greg Fraser asked for an explanation regarding the higher-than-expected cash balance at year-end and what additional levers exist to lower cash costs moving forward.

Answer

Jamey Mock, CFO, explained the higher cash balance by detailing how actual cash costs were $1.2 billion lower than original guidance, plus a $600 million credit facility draw, $100 million less in capital expenditures, and $200 million from strong working capital performance.

Ask follow-up questions

Fintool

Fintool can write a report on Moderna logo MRNA's next earnings in your company's style and formatting